Cowen analyst Doug Schenkel says he confirmed with Dexcom management that today's Centers for Medicare & Medicaid Services decision covers all relevant Durable Medical Equipment Medicare Administrative Contractors and that pricing is expected to be stable with the original CMS announcement. This is "clearly a broader decision that occurred more quickly than expected," Schenkel tells investors in a research note. Today's announcement confirms the inclusion of intensively managed Type 2 patients, which is a "big deal" as it brings the total CMS reimbursed patient population to over 1M, the analyst adds. He has an Outperform rating on Dexcom with a $90 price target. The stock in morning trading is up 9% to $83.00.